The effect of desogestrel, gestodene, and other factors on spotting and bleeding

Contraception

Volumn 53, Issue 2, 1996, Pages 85-90

  Rosenberg, Michael J ^a,b   Waugh, Michael S ^a   Higgins, James E ^a  

^a Health Decisions Inc   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

cycle control; desogestrel; gestodene; progestin

Indexed keywords

DESOGESTREL; ETHINYLESTRADIOL; GESTAGEN; GESTODENE; ORAL CONTRACEPTIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; BREAKTHROUGH BLEEDING; CIGARETTE SMOKING; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MENSTRUATION DISORDER; MULTICENTER STUDY; ORAL CONTRACEPTION; ORAL DRUG ADMINISTRATION; RISK ASSESSMENT; RISK FACTOR; SPOTTING;

EID: 0030050324     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/0010-7824(95)00270-7     Document Type: Article

References (18)

1. Hillard PJ. The patient's reaction to side effects of oral contraceptives. Am J Obstet Gynecol 1989;161:1412-5.
2. Pratt WF, Bachrach CC. What do women use when they stop using the pill? Fam Plann Perspect 1987;19:257-66.
3. Rosenberg MJ, Waugh ME, Long SL. Unintended pregnancies due to oral contraceptive discontinuation: the neglected consequence of poor OC use. J Reprod Med 1995;40:355-60.
4. Chez RA. Clinical aspects of three new progestogens: Desogestrel, gestodene, and norgestimate. Am J Obstet Gynecol 1989;160:1296-300.
5. Rosenberg MJ, Long SC. Oral contraceptives and cycle control: a critical review of the literature. Adv Contraception 1992;8(Suppl 1):35-45.
6. Speroff L, DeCherney A, Advisory Board for New Progestins. Evaluation of a new generation of oral contraceptives. Obstet Gynecol 1993;81:1034-47.
7. Benagiano G. Comparison of two monophasic oral contraceptives: Gestodene/ethinyl estradiol versus desogestrel/ethinyl estradiol. Int J Fertil 1989;34:31-9.
8. Statistics and Epidemiology Research Corporation. EGRET Statistical Software. Seattle: SERC Inc., 1991.
9. Greenland S. Modeling and variable selection in epidemiologic analysis. Am J Public Health 1989;79:340-9.
10. Norusis MJ, SPSS Inc. SPSS Advanced Statistics 6.1. Chicago, IL:SPSS Inc., 1994.
11. Breslow NE, Day NE. Statistical Methods in Cancer Research, Volume 1: The Analysis of Case-Control Studies. Lyon:International Agency for Research on Cancer, 1980.
12. Christie T. A clinical overview of a new triphasic contraceptive containing gestodene. Int J Fertil 1989;34 (Suppl):40-9.
13. Oxman AD, Clarke MJ, Stewart LA. From science to practice: Meta-analyses using individual patient data are needed. JAMA 1995;274:845-6.
14. Sparrow MJ. Pregnancies in reliable pill takers. NZ Med J 1989;102:575-7.
15. Wald N, Baron J, eds. Smoking and hormone-related disorders. New York:Oxford University, 1990.
16. Stadel BV, Sternthal PM, Schlesselman JJ, et al. Variation of ethinylestradiol blood levels among healthy women using oral contraceptives. Fertil Steril 1980;33: 257-60.
17. Kanarkowski R, Tornoatore KM, D'Ambrosio R, Gardner MJ, Jusko WJ. Pharmacokinetics of single and multiple doses of ethinyl estradiol and levonorgestrel in relation to smoking. Clin Pharmacol Ther 1988;43:25-31.
18. Fotherby K, Caldwell DS. New progestins in oral contraception. Contraception 1994;49:1-32.